GLUE · Monte Rosa Therapeutics, Inc.

The thesis

Monte Rosa Therapeutics now has two Novartis-funded Phase 2 starts for MRT-6160 paying milestones, but the value-defining test of its inflammation drug MRT-8102 (GFORCE-2 in heart disease, guided for the first half of 2027) is still months away. The third-quarter report, expected in early November 2026, shows whether spending and start dates hold.

On 28 October 2026 the company announced that Novartis started a second Phase 2 study of MRT-6160 in active moderate to severe psoriatic arthritis, which triggers a $37.5 million milestone payable on the first patient visit (company release, 28 October 2026). The first milestone, $50 million for the Sjögren's disease study, was announced on 8 September 2026.

The narrative is maturing: the MRT-8102 Phase 1 data are public (1 October 2026) and the partner milestones are now arriving on a predictable schedule, so fresh attention depends on events in 2027. MRT-8102's 1 October 2026 data showed a median 85% fall in high-sensitivity C-reactive protein (hsCRP, an inflammation marker) in 108 obese subjects with elevated cardiovascular risk, with no serious adverse events (company release, 1 October 2026). Novo Nordisk's ZEUS trial of ziltivekimab, which targets the same inflammatory pathway, reported a major adverse cardiovascular event hazard ratio of 0.99 (TCTMD, 3 August 2026), so heart-disease outcomes evidence, not biomarkers, settles the case.

Bullish and bearish views on Monte Rosa Therapeutics, Inc.

The bull case on Monte Rosa Therapeutics, Inc. (GLUE), in brief: Partner milestones keep arriving. The bear case: The heart-disease trial starts later than guided.

Bull case

• Partner milestones keep arriving. Novartis' first patient visit in the Sjögren's Phase 2 study triggered $50 million (announced 8 September 2026). The psoriatic arthritis study adds $37.5 million on its first patient visit (company release, 28 October 2026). The company has said it expects further Phase 2 activations across immune-mediated diseases.
• Novartis carries Phase 2 cost. Under the agreement, Novartis conducts and funds MRT-6160 Phase 2 development, and Monte Rosa shares 30% of U.S. profits and losses if Phase 3 starts (company announcement, 8 September 2026). The deal allows up to $2.1 billion in development, regulatory and sales milestones (company filings).
• The two milestones were announced after that date.
• MRT-8102 safety was clean. Treatment-emergent adverse events were 33% on MRT-8102 against 30% on placebo, with no serious events (company release, 1 October 2026).
• Analyst targets sit far above the share price. HC Wainwright reiterated Buy with a $25 target on 5 October 2026. Wedbush reiterated Outperform with a $27 target on 9 September 2026. Guggenheim's target was $35 on 30 June 2026.

Bear case

• The heart-disease trial starts later than guided. The 1 October 2026 release places GFORCE-2 in coronary artery disease in the first half of 2027, after earlier guidance for the second half of 2026. The shares fell 6.41% to $11.17 in the 1 October 2026 session (Benzinga).
• Inflammation markers have not predicted outcomes in this class. ZEUS reported a hazard ratio of 0.99 on 31 July 2026 (TCTMD, 3 August 2026). A four-week study in 108 subjects cannot show event reduction.
• Spending is rising. Second-quarter research and development expense was $48.0 million against $30.7 million a year earlier (company results, 6 August 2026). Second-quarter revenue was $8.97 million against an expected $12.91 million, and the loss per share was $0.43 against a consensus loss of $0.38 (MarketBeat, 5 October 2026).
• The milestone revenue is lumpy. Milestones depend on partner trial starts and do not recur on a fixed calendar. A single quarter with a payment will not show underlying spending.
• The next dated MRT-8102 events fall in 2027. GEMINI-1 in gout is guided for Q4 2026 or Q1 2027, and GFORCE-2 and GALAXY-1 in hidradenitis suppurativa for the first half of 2027 (company release, 1 October 2026). The ziltivekimab outcomes trials HERMES and ARTEMIS, also guided for H1 2027, can move sentiment on the class without any Monte Rosa disclosure.

Price setup

The adjusted close on 28 October 2026 was $10.85, which is 57.1% below the 52-week high of $25.31 and 34.3% lower than three months earlier. The 14-day relative strength index (a 0-100 momentum gauge) was 56.0, against 29.3 on 15 October 2026 and 15.2 on 2 October 2026. The shares have recovered from oversold readings but remain far below the summer range.

The close of $10.12 on 15 October 2026 is the nearest recent reference low in the adjusted closes. The invalidation level of $9.50 sits below it.

Crowding evidence is thin. The next earnings report is days away, which concentrates risk in a single session. No SEC filings were published in the last 30 days, so there are no insider-sale or share-issuance filings to cite.

Catalysts, next 30 days

• ~9 November 2026, est.: Third-quarter 2026 results and business update. EarningsWhispers projects 9 November 2026 before the market opens and a consensus loss of $0.10 per share; the company has not confirmed the date, and it reported on 6 November 2025 last year. The report shows research and development spending against the $48.0 million second-quarter level and whether the 2027 start dates hold.
• Q4 2026 or Q1 2027: GEMINI-1 Phase 2 start in gout flares. This is the nearest dated clinical step for MRT-8102 and falls outside the 30-day window.
• Any further Novartis Phase 2 start for MRT-6160. The company has said more starts are expected, and each would trigger a further milestone; no date is given.

What would change the view

The case would break if MRT-8102 shows a serious-infection imbalance in longer-exposure cohorts, or if GFORCE-2 slips beyond the first half of 2027 or drops a cardiovascular-events endpoint. Third-quarter research and development spending well above $48.0 million, or use of an at-the-market share program, would weaken the cash-runway leg. A further inflammation-class outcomes failure in HERMES or ARTEMIS would raise the doubt about the biomarker link.

The price condition is a daily close below $9.50, which sits below the 15 October 2026 close of $10.12. On the upside, a GFORCE-2 design built on hard cardiovascular events with a confirmed start date would strengthen the case.

What it trades with

Monte Rosa's heart-disease story trades with the anti-inflammatory cardiovascular class, so ziltivekimab outcomes news from Novo Nordisk moves sentiment on the shares (ZEUS, 31 July 2026). The MRT-6160 program is tied to Novartis' development pace, and its milestones do not depend on MRT-8102 results. Small clinical-stage biotech shares also tend to move with broad risk appetite in the sector.